Union Rate and Complications in Spine Fusion with Recombinant Human Bone Morphogenetic Protein-7: Systematic Review and Meta-Analysis
dc.contributor.author | Vavken, Julia | en_US |
dc.contributor.author | Vavken, Patrick | en_US |
dc.contributor.author | Mameghani, Alexander | en_US |
dc.contributor.author | Schaeren, Stefan | en_US |
dc.date.accessioned | 2016-04-01T15:48:08Z | |
dc.date.issued | 2015 | en_US |
dc.identifier.citation | Vavken, Julia, Patrick Vavken, Alexander Mameghani, and Stefan Schaeren. 2015. “Union Rate and Complications in Spine Fusion with Recombinant Human Bone Morphogenetic Protein-7: Systematic Review and Meta-Analysis.” Global Spine Journal 6 (2): 124-132. doi:10.1055/s-0035-1557143. http://dx.doi.org/10.1055/s-0035-1557143. | en |
dc.identifier.issn | 2192-5682 | en |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318648 | |
dc.description.abstract | Study Design Systematic review and meta-analysis. Objective: The objective of this meta-analysis was to evaluate the current best evidence to assess effectiveness and safety of recombinant human bone morphogenetic protein-7 (rhBMP-7) as a biological stimulant in spine fusion. Methods: Studies were included if they reported on outcomes after spine fusion with rhBMP-7. The data was synthesized using Mantel-Haenszel pooled risk ratios (RRs) with 95% confidence intervals (CIs). Main end points were union rate, overall complications, postoperative back and leg pain, revision rates, and new-onset cancer. Results: Our search produced 796 studies, 6 of which were eligible for inclusion. These studies report on a total of 442 patients (328 experimental, 114 controls) with a mean age of 59 ± 11 years. Our analysis showed no statistically significant differences in union rates (RR 0.97, 95% CI 0.84 to 1.11, p = 0.247), overall complications (RR 0.92, 95% CI 0.71 to 1.20, p = 0.545), postoperative back and leg pain (RR 1.03, 95% CI 0.48 to 2.19, p = 0.941), or revision rate (RR 0.81, 95% CI 0.47 to 1.40, p = 0.449). There was a mathematical indicator of increased tumor rates, but with only one case, the clinical meaningfulness of this finding is questionable. Conclusion: We were not able to find data in support of the use of rhBMP-7 for spine fusion. We found no evidence for increased complication or revision rates with rhBMP-7. On the other hand, we also found no evidence in support of improved union rates. | en |
dc.language.iso | en_US | en |
dc.publisher | Georg Thieme Verlag KG | en |
dc.relation.isversionof | doi:10.1055/s-0035-1557143 | en |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771504/pdf/ | en |
dash.license | LAA | en_US |
dc.subject | spine | en |
dc.subject | fusion | en |
dc.subject | rhBMP-7 | en |
dc.subject | complications | en |
dc.title | Union Rate and Complications in Spine Fusion with Recombinant Human Bone Morphogenetic Protein-7: Systematic Review and Meta-Analysis | en |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en |
dc.relation.journal | Global Spine Journal | en |
dash.depositing.author | Vavken, Patrick | en_US |
dc.date.available | 2016-04-01T15:48:08Z | |
dc.identifier.doi | 10.1055/s-0035-1557143 | * |
dash.authorsordered | false | |
dash.contributor.affiliated | Vavken, Patrick |
Files in this item
This item appears in the following Collection(s)
-
HMS Scholarly Articles [17928]